NOVO HOLDINGS A/S
HELLERUP, G7 · CIK 1388325 · 13F filing filed 2026-08-14
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityNovo Holdings A/S (DK)
- Part of Novo Nordisk Fonden (DK)
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| EDGEWISE THERAPEUTICS INC EWTX | $217.4m12.62% | Unchanged |
| ASML HOLDING N V ASML | $188.9m10.97% | Unchanged |
| HEMAB THERAPEUTICS HLDGS INC COAG | $153.6m8.92% | New |
| BROOKFIELD CORP BN | $149.5m8.68% | Unchanged |
| MAPLIGHT THERAPEUTICS INC MPLT | $132.1m7.67% | Unchanged |
| MIRUM PHARMACEUTICALS INC MIRM | $131.7m7.65% | Reduced -200.0k |
| AVALYN PHARMACEUTICALS INC AVLN | $127.8m7.42% | New |
| SALESFORCE INC CRM | $61.6m3.58% | Unchanged |
| ARRIVENT BIOPHARMA INC AVBP | $52.1m3.03% | Reduced -442.1k |
| ENLIVEN THERAPEUTICS INC ELVN | $50.8m2.95% | Reduced -280.0k |
| CRINETICS PHARMACEUTICALS IN CRNX | $49.4m2.87% | Reduced -230.0k |
| PHARVARIS N V PHVS | $48.4m2.81% | Reduced -350.0k |
| FLOOR & DECOR HLDGS INC FND | $47.3m2.75% | New |
| VAXCYTE INC PCVX | $46.5m2.70% | Reduced -60.0k |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $43.2m2.51% | Reduced -401.6k |
| VIRIDIAN THERAPEUTICS INC VRDN | $39.2m2.28% | Added +135.0k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $38.1m2.21% | Reduced -175.0k |
| ALUMIS INC ALMS | $31.0m1.80% | New |
| XENON PHARMACEUTICALS INC XENE | $29.3m1.70% | Unchanged |
| ALIBABA GROUP HLDG LTD BABA | $24.7m1.43% | Unchanged |
| DYNE THERAPEUTICS INC DYN | $21.3m1.24% | New |
| BRIDGEBIO ONCOLOGY THERAPEUT BBOT | $17.1m1.00% | Added +64.1k |
| INSMED INC INSM | $12.9m0.75% | New |
| MARQETA INC CLASS A COM | $7.2m0.42% | Unchanged |
| LANZATECH GLOBAL INC LNZA | $1.1m0.06% | Unchanged |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| APOGEE THERAPEUTICS INC | $37.9m450.0k shares |
| BIOMARIN PHARMACEUTICAL INC BMRN | $37.3m660.0k shares |
| VALNEVA SE VALN | $6.6m1.1m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| HEMAB THERAPEUTICS HLDGS INC COAG · 13G · filed 2026-08-14 | 9.0%≈ $153.6m |
| AVALYN PHARMACEUTICALS INC AVLN · 13G · filed 2026-08-14 | 8.8%≈ $127.8m |
| 4D MOLECULAR THERAPEUTICS IN FDMT · 13G · filed 2026-02-17 | 6.4%≈ $46.6m |
Trades reported as a company insider since 1 Apr 2026
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2026-05-01 | AVALYN PHARMACEUTICALS INC 10% owner | Bought | $10.0m555.6k shares |